BACKGROUND: Portal vein embolisation (PVE) induces contra-lateral liver hypertrophy to facilitate an extended hepatectomy. AIM: This paper aims to analyse our data on PVE and extended hepatectomy. Outcome measures included success of PVE, feasibility of resections, operative morbidity and survival. METHODS: A retrospective analysis of data collected prospectively on 33 patients (2004-2008) was performed. Survival curves were estimated by the Kaplan-Meier (Breslow) method. Significance was defined as p < 0.05. RESULTS: A total of 31 patients had successful PVE. There were 24 patients who underwent surgery. Significant hypertrophy of residual liver was noted from 230.15 (pre-embolisation) to 428.50 ml (post-embolisation) (median, p < 0.0001). A total of 16 patients had hepatectomy (14: R0; 2: R1) with a single mortality (6.25%) and 56.25% morbidity, and a median length of stay of 17 days. Median overall survival was 14 (95% CI 7.8-20.2) months. Patients who underwent resection had a median disease-specific survival of 33 (95% CI 4-62) months compared with 8.6 (95% CI 0-19.9) months for patients without resection (p = 0.14). For patients with primary hepato-biliary tumours, the median disease-specific survival was 7.9 (95% CI 4.5-11.3) months compared with a median survival of 19.7 (95% CI 0-42.2) months for patients with metastases (p = 0.07). CONCLUSIONS: PVE is safe, facilitates R0 resection and offers the best chance of cure, especially for liver metastases.
BACKGROUND: Portal vein embolisation (PVE) induces contra-lateral liver hypertrophy to facilitate an extended hepatectomy. AIM: This paper aims to analyse our data on PVE and extended hepatectomy. Outcome measures included success of PVE, feasibility of resections, operative morbidity and survival. METHODS: A retrospective analysis of data collected prospectively on 33 patients (2004-2008) was performed. Survival curves were estimated by the Kaplan-Meier (Breslow) method. Significance was defined as p < 0.05. RESULTS: A total of 31 patients had successful PVE. There were 24 patients who underwent surgery. Significant hypertrophy of residual liver was noted from 230.15 (pre-embolisation) to 428.50 ml (post-embolisation) (median, p < 0.0001). A total of 16 patients had hepatectomy (14: R0; 2: R1) with a single mortality (6.25%) and 56.25% morbidity, and a median length of stay of 17 days. Median overall survival was 14 (95% CI 7.8-20.2) months. Patients who underwent resection had a median disease-specific survival of 33 (95% CI 4-62) months compared with 8.6 (95% CI 0-19.9) months for patients without resection (p = 0.14). For patients with primary hepato-biliary tumours, the median disease-specific survival was 7.9 (95% CI 4.5-11.3) months compared with a median survival of 19.7 (95% CI 0-42.2) months for patients with metastases (p = 0.07). CONCLUSIONS: PVE is safe, facilitates R0 resection and offers the best chance of cure, especially for liver metastases.
Authors: J N Vauthey; A Chaoui; K A Do; M M Bilimoria; M J Fenstermacher; C Charnsangavej; M Hicks; G Alsfasser; G Lauwers; I F Hawkins; J Caridi Journal: Surgery Date: 2000-05 Impact factor: 3.982
Authors: Lorenzo Capussotti; Andrea Muratore; Alessandro Ferrero; Giovanni Carlo Anselmetti; Andrea Corgnier; Daniele Regge Journal: Arch Surg Date: 2005-11
Authors: Donatella R Di Stefano; Thierry de Baere; Alban Denys; Antoine Hakime; Gilles Gorin; Michel Gillet; Jean Saric; Hervé Trillaud; Philippe Petit; Jean-Michel Bartoli; Dominique Elias; Jean-Robert Delpero Journal: Radiology Date: 2004-12-10 Impact factor: 11.105
Authors: Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; Felice Giuliante; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston Journal: Eur J Cancer Date: 2007-09-04 Impact factor: 9.162
Authors: Alan W Hemming; Alan I Reed; Richard J Howard; Shiro Fujita; Steven N Hochwald; James G Caridi; Irvin F Hawkins; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2003-05 Impact factor: 12.969